Financials

Valore Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25 TTM
Key stats
Valuation ratios
Profitability ratios
Liquidity ratios
Solvency ratios
Per share metrics

Kyntra Bio Inc

Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate. On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB.